321 related articles for article (PubMed ID: 27911856)
1. Splicing factor ratio as an index of epithelial-mesenchymal transition and tumor aggressiveness in breast cancer.
Fici P; Gallerani G; Morel AP; Mercatali L; Ibrahim T; Scarpi E; Amadori D; Puisieux A; Rigaud M; Fabbri F
Oncotarget; 2017 Jan; 8(2):2423-2436. PubMed ID: 27911856
[TBL] [Abstract][Full Text] [Related]
2. Splicing factor
Gökmen-Polar Y; Neelamraju Y; Goswami CP; Gu Y; Gu X; Nallamothu G; Vieth E; Janga SC; Ryan M; Badve SS
EMBO Rep; 2019 Feb; 20(2):. PubMed ID: 30665944
[TBL] [Abstract][Full Text] [Related]
3. An EMT-driven alternative splicing program occurs in human breast cancer and modulates cellular phenotype.
Shapiro IM; Cheng AW; Flytzanis NC; Balsamo M; Condeelis JS; Oktay MH; Burge CB; Gertler FB
PLoS Genet; 2011 Aug; 7(8):e1002218. PubMed ID: 21876675
[TBL] [Abstract][Full Text] [Related]
4. The RNA-binding protein Rbfox2: an essential regulator of EMT-driven alternative splicing and a mediator of cellular invasion.
Braeutigam C; Rago L; Rolke A; Waldmeier L; Christofori G; Winter J
Oncogene; 2014 Feb; 33(9):1082-92. PubMed ID: 23435423
[TBL] [Abstract][Full Text] [Related]
5. Alternative splicing modulates cancer aggressiveness: role in EMT/metastasis and chemoresistance.
Roy Burman D; Das S; Das C; Bhattacharya R
Mol Biol Rep; 2021 Jan; 48(1):897-914. PubMed ID: 33400075
[TBL] [Abstract][Full Text] [Related]
6. Altered Expression and Splicing of ESRP1 in Malignant Melanoma Correlates with Epithelial-Mesenchymal Status and Tumor-Associated Immune Cytolytic Activity.
Yao J; Caballero OL; Huang Y; Lin C; Rimoldi D; Behren A; Cebon JS; Hung MC; Weinstein JN; Strausberg RL; Zhao Q
Cancer Immunol Res; 2016 Jun; 4(6):552-61. PubMed ID: 27045022
[TBL] [Abstract][Full Text] [Related]
7. Coregulation of alternative splicing by hnRNPM and ESRP1 during EMT.
Harvey SE; Xu Y; Lin X; Gao XD; Qiu Y; Ahn J; Xiao X; Cheng C
RNA; 2018 Oct; 24(10):1326-1338. PubMed ID: 30042172
[TBL] [Abstract][Full Text] [Related]
8. A Regulatory Axis between Epithelial Splicing Regulatory Proteins and Estrogen Receptor α Modulates the Alternative Transcriptome of Luminal Breast Cancer.
Elhasnaoui J; Ferrero G; Miano V; Franchitti L; Tarulli I; Coscujuela Tarrero L; Cutrupi S; De Bortoli M
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887187
[TBL] [Abstract][Full Text] [Related]
9. Epithelial splicing regulatory protein 1 and 2 paralogues correlate with splice signatures and favorable outcome in human colorectal cancer.
Deloria AJ; Höflmayer D; Kienzl P; Łopatecka J; Sampl S; Klimpfinger M; Braunschmid T; Bastian F; Lu L; Marian B; Stättner S; Holzmann K
Oncotarget; 2016 Nov; 7(45):73800-73816. PubMed ID: 27650542
[TBL] [Abstract][Full Text] [Related]
10. Roles and Regulation of Epithelial Splicing Regulatory Proteins 1 and 2 in Epithelial-Mesenchymal Transition.
Göttgens EL; Span PN; Zegers MM
Int Rev Cell Mol Biol; 2016; 327():163-194. PubMed ID: 27692175
[TBL] [Abstract][Full Text] [Related]
11. Determination of a Comprehensive Alternative Splicing Regulatory Network and Combinatorial Regulation by Key Factors during the Epithelial-to-Mesenchymal Transition.
Yang Y; Park JW; Bebee TW; Warzecha CC; Guo Y; Shang X; Xing Y; Carstens RP
Mol Cell Biol; 2016 Jun; 36(11):1704-19. PubMed ID: 27044866
[TBL] [Abstract][Full Text] [Related]
12. Relationship between circulating tumor cells and epithelial to mesenchymal transition in early breast cancer.
Mego M; Cierna Z; Janega P; Karaba M; Minarik G; Benca J; Sedlácková T; Sieberova G; Gronesova P; Manasova D; Pindak D; Sufliarsky J; Danihel L; Reuben JM; Mardiak J
BMC Cancer; 2015 Jul; 15():533. PubMed ID: 26194471
[TBL] [Abstract][Full Text] [Related]
13. Snail represses the splicing regulator epithelial splicing regulatory protein 1 to promote epithelial-mesenchymal transition.
Reinke LM; Xu Y; Cheng C
J Biol Chem; 2012 Oct; 287(43):36435-42. PubMed ID: 22961986
[TBL] [Abstract][Full Text] [Related]
14. The oncogenic kinase NEK2 regulates an RBFOX2-dependent pro-mesenchymal splicing program in triple-negative breast cancer cells.
Naro C; De Musso M; Delle Monache F; Panzeri V; de la Grange P; Sette C
J Exp Clin Cancer Res; 2021 Dec; 40(1):397. PubMed ID: 34930366
[TBL] [Abstract][Full Text] [Related]
15. The pro-metastasis effect of circANKS1B in breast cancer.
Zeng K; He B; Yang BB; Xu T; Chen X; Xu M; Liu X; Sun H; Pan Y; Wang S
Mol Cancer; 2018 Nov; 17(1):160. PubMed ID: 30454010
[TBL] [Abstract][Full Text] [Related]
16. Emerging Multi-cancer Regulatory Role of ESRP1: Orchestration of Alternative Splicing to Control EMT.
Vadlamudi Y; Dey DK; Kang SC
Curr Cancer Drug Targets; 2020; 20(9):654-665. PubMed ID: 32564755
[TBL] [Abstract][Full Text] [Related]
17. The long non-coding RNA MALAT1 promotes ovarian cancer progression by regulating RBFOX2-mediated alternative splicing.
Gordon MA; Babbs B; Cochrane DR; Bitler BG; Richer JK
Mol Carcinog; 2019 Feb; 58(2):196-205. PubMed ID: 30294913
[TBL] [Abstract][Full Text] [Related]
18. ESRP1 as a prognostic factor of non-small-cell lung cancer is related to the EMT transcription factor of Twist.
Cui J; Ren P; Li Y; Ma Y; Wang J; Lin C; Jing L; Tong X; Ma S; Chen J
Thorac Cancer; 2021 Sep; 12(18):2449-2457. PubMed ID: 34342121
[TBL] [Abstract][Full Text] [Related]
19. Epithelial splicing regulatory protein 1 and 2 (ESRP1 and ESRP2) upregulation predicts poor prognosis in prostate cancer.
Freytag M; Kluth M; Bady E; Hube-Magg C; Makrypidi-Fraune G; Heinzer H; Höflmayer D; Weidemann S; Uhlig R; Huland H; Graefen M; Bernreuther C; Wittmer C; Tsourlakis MC; Minner S; Dum D; Hinsch A; Luebke AM; Simon R; Sauter G; Schlomm T; Möller K
BMC Cancer; 2020 Dec; 20(1):1220. PubMed ID: 33339518
[TBL] [Abstract][Full Text] [Related]
20. Epithelial splicing regulatory proteins 1 (ESRP1) and 2 (ESRP2) suppress cancer cell motility via different mechanisms.
Ishii H; Saitoh M; Sakamoto K; Kondo T; Katoh R; Tanaka S; Motizuki M; Masuyama K; Miyazawa K
J Biol Chem; 2014 Oct; 289(40):27386-99. PubMed ID: 25143390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
